Neumora Therapeutics upgraded to Outperform from Sector Perform at RBC Capital

RBC Capital upgraded Neumora Therapeutics (NMRA) to Outperform from Sector Perform with a price target of $7, up from $4. The company is evolving beyond neurology, which is not yet reflected in the shares, the analyst tells investors in a research note. The firm believes Neumora is well positioned with a competitive early asset in an NLRP3 class demonstrating “emerging promise across multiple large-market indications,” including obesity and cardiometabolic disease. Data in 2026 should better define the target’s potential and could have meaningful positive readthroughs to Neumora, contends RBC.